← Back to Clinical Trials
Recruiting NCT06416150

NCT06416150 Reducing Urban Cervical Cancer Disparities

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06416150
Status Recruiting
Phase
Sponsor Fox Chase Cancer Center
Condition Cervical Cancer
Study Type INTERVENTIONAL
Enrollment 546 participants
Start Date 2024-08-28
Primary Completion 2027-04

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 90 Years
Study Type INTERVENTIONAL
Interventions
Stage 1 SOCStage 1 HERSStage 2 HERS

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 546 participants in total. It began in 2024-08-28 with a primary completion date of 2027-04.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study uses a hybrid Type 1 effectiveness-implementation trial to operationalize and assess the efficacy of the Health Enhancement Resource System (HERS) intervention. HERS aims to increase patient follow-up after abnormal test results through text message-based barriers counseling for women and supplemental telephone-based Health Coaching for women who miss their appointment.

Eligibility Criteria

Inclusion Criteria: * 18 to 90 years of age (screening is still recommended for some women over 65-depending on screening and medical history and proceeds until age 90 in the study's clinic recruitment sites), * referral for colposcopic evaluation at the clinic sites, * able to communicate with ease in English, * have a cell phone with texting ability, and * competent to give consent. Exclusion Criteria: * are pregnant at the time of recruitment, * display current evidence or have a history of positive invasive carcinoma of the cervix, or * require follow-up but not a colposcopy.

Contact & Investigator

Central Contact

Suzanne M Miller, PhD

✉ suzanne.miller@fccc.edu

📞 215-728-4069

Principal Investigator

Suzanne M Miller, PhD

PRINCIPAL INVESTIGATOR

Fox Chase Cancer Center

Frequently Asked Questions

Who can join the NCT06416150 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 90 Years, studying Cervical Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06416150 currently recruiting?

Yes, NCT06416150 is actively recruiting participants. Contact the research team at suzanne.miller@fccc.edu for enrollment information.

Where is the NCT06416150 trial being conducted?

This trial is being conducted at New Brunswick, United States, Philadelphia, United States, Philadelphia, United States.

Who is sponsoring the NCT06416150 clinical trial?

NCT06416150 is sponsored by Fox Chase Cancer Center. The principal investigator is Suzanne M Miller, PhD at Fox Chase Cancer Center. The trial plans to enroll 546 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology